A phase I/II study of CYC065 in combination with venetoclax for patients with relapsed or refractory chronic lymphocytic leukemia

Trial Profile

A phase I/II study of CYC065 in combination with venetoclax for patients with relapsed or refractory chronic lymphocytic leukemia

Planning
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs CYC 065 (Primary) ; Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Mar 2018 According to a Cyclacel Pharmaceuticals media release, the protocol has been submitted to the US Food and Drug Administration or FDA.
    • 09 Jan 2018 According to a Cyclacel Pharmaceuticals media release, company is planning to initiate this trial in 2018.
    • 16 Nov 2017 Phase was mentioned as I/II based on MR 9221117. I have changed phase to Ib based on the recent MR 9226634.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top